TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis

Immune checkpoint blockade therapy has demonstrated promising clinical outcomes for multiple cancer types. However, the emergence of resistance as well as inadequate biomarkers for patient stratification have largely limited the clinical benefits. Here, we showed that tumors with high TYRO3 expressi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Invest
Main Authors: Jiang, Zhou, Lim, Seung-Oe, Yan, Meisi, Hsu, Jennifer L., Yao, Jun, Wei, Yongkun, Chang, Shih-Shin, Yamaguchi, Hirohito, Lee, Heng-Huan, Ke, Baozhen, Hsu, Jung-Mao, Chan, Li-Chuan, Hortobagyi, Gabriel N., Yang, Liuqing, Lin, Chunru, Yu, Dihua, Hung, Mien-Chie
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Clinical Investigation 2021
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8262501/
https://ncbi.nlm.nih.gov/pubmed/33855973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI139434
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares